Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
CRISPR Therapeutics AG incurred convertible notes of $600.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at effective coupon of 1.125%, increased to 1.7308% maturing March 1, 2031.
- Instrument
- convertible notes
- Principal
- $600.0 million aggregate principal amount
- Counterparty
- U.S. Bank Trust Company, National Association
- Rate
- effective coupon of 1.125%, increased to 1.7308%
- Maturity
- March 1, 2031
- Event
- incurrence
Exact text from the filing
On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
CRISPR Therapeutics AG issued 11,363,580 Common Shares may be delivered upon conversion of the Notes of convertible note to qualified institutional buyers for $600.0 million aggregate principal amount of Convertible Senior Notes due 2031.
- Security
- convertible note
- Shares
- 11,363,580 Common Shares may be delivered upon conversion of the Notes
- Purchaser
- qualified institutional buyers
- Consideration
- $600.0 million aggregate principal amount of Convertible Senior Notes due 2031
Exact text from the filing
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01. Entry into a Material Definitive Agreement. On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CRISPR Therapeutics AG entered into Indenture with U.S. Bank Trust Company, National Association valued at $600.0 million aggregate principal amount (effective 2026-03-16).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- U.S. Bank Trust Company, National Association
- Value
- $600.0 million aggregate principal amount
- Effective
- 2026-03-16
Exact text from the filing
On March 16, 2026, CRISPR Therapeutics AG (the “Company”) completed its previously announced private offering (the “Offering”) of $600.0 million aggregate principal amount of its Convertible Senior Notes due 2031 (the “Notes”)
View on SEC.gov